Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1EV
|
|||
| Former ID |
DAP001111
|
|||
| Drug Name |
Cyclopentolate
|
|||
| Synonyms |
Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Examination of eyes or vision [ICD-11: QA00.6; ICD-10: H57.04] | Approved | [1] | |
| Therapeutic Class |
Parasympatholytics
|
|||
| Company |
Akorn Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H25NO3
|
|||
| Canonical SMILES |
CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
|
|||
| InChI |
1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
|
|||
| InChIKey |
SKYSRIRYMSLOIN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 512-15-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9149, 7407707, 7849628, 7979008, 8151860, 10524721, 11335785, 11361024, 11363750, 11366312, 11368874, 11371417, 11374025, 11377036, 11461996, 11467123, 11468243, 11484719, 11486791, 11488938, 11490185, 11492118, 11494670, 15270905, 29222058, 46504517, 47291117, 47662272, 48035106, 48184981, 48184982, 48259220, 48259221, 49698850, 50064835, 50143250, 51092051, 85209515, 85788899, 92714642, 96079578, 103812003, 104301961, 117582369, 124883485, 126407497, 126623975, 126683178, 129251393, 131273740
|
|||
| ChEBI ID |
CHEBI:4024
|
|||
| ADReCS Drug ID | BADD_D00547 ; BADD_D00548 | |||
| SuperDrug ATC ID |
S01FA04
|
|||
| SuperDrug CAS ID |
cas=000512152
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M5 (CHRM5) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Muscarinic acetylcholine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.